Skip Navigation

Annals of Oncology 2006 17(Supplement 5):v195-v198; doi:10.1093/annonc/mdj980
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Galligioni, E.
Right arrow Articles by Griso, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galligioni, E.
Right arrow Articles by Griso, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Gemcitabine and anthracyclines in platinum-resistant ovarian cancer

E. Galligioni1,*, C. Arcuri1, R. Sorio2 and C. Griso3

Medical Oncology, 1 Trento, 2 CRO Aviano, 3 Verona, Italy

* Correspondence to: Dr E. Galligioni, Medical Oncology, St. Chiara Hospital, 38100 Trento, Italy. Tel: +39 0461 902478; Fax: +39 0461 903364; E-mail: enzo.galligioni{at}apss.tn.it

Background: Most of the patients with advanced ovarian cancer will recur after first-line platinum-based chemotherapy and need additional treatment. Gemcitabine (G) and Anthracyclines are active in this setting and their combination has shown synergistic antiproliferative activity in vitro, due to different mechanisms of action and non-overlapping toxicities.

Patients and methods: In 2002 we began a phase II study with G 1000 mg/m2 (day 1,8) combined to Epirubicin (E) 60 mg/m2 (day 1), every 3 weeks for 6 cycles, in Platinum resistant/refractory ovarian carcinoma patients.

Results: Among 30 patients enrolled so far (27 evaluable), receiving 149 cycles (median 6), 1 complete and 12 partial responses (48%), 9 stabilizations (33%) and 5 progressions (18%) were observed, with a good correlation with serological responses. Median time to progression was 8 months, while median time to response was 10 weeks and median duration 8 months. Grade 3–4 toxicities consisted of neutropenia (58%), thrombocytopenia (3%), anemia (10%), liver toxicity (13%), and mucositis (7%). Eight patients (27%) received G-CSF and 3 (10%) blood transfusions. No febrile neutropenia nor cardiotoxicity were observed.

Conclusions: Although our results are preliminary, G/E combination appears particularly effective and safe in these platinum resistant/refractory patients.

Key words: recurrent ovarian cancer, platinum-resistant patients, gemcytabine-antracyclines combination


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.